We are excited to share two valuable resources: our two-part webinar series “Demystifying the ATTUNE Study”, and an e-booklet with questions from families all over the world. These resources aim to provide detailed and accessible information to families and professionals about the first clinical trial for ION440, which has recently started recruiting patients in the US.
The first webinar of the series offers an explanation of MDS and the mechanism of action of ION440 while delving into critical aspects of clinical trial design, regulatory steps, and eligibility criteria for participation.
This first part provides the fundamental knowledge families need to better understand the study and its potential impact.
The second webinar builds on this foundation, addressing additional questions such as the medical procedure for administering ION440, the sham control group, the expected benefits, costs and communication of the next steps after ATTUNE. The second part is an essential resource for anyone looking for practical information about the ATTUNE study. Both parts of the webinar are now available to watch on our YouTube channel.
To complement the webinars, we have also released an e-booklet, a guide created from over 150 questions collected from families from 18 different countries. The booklet addresses logistical concerns about the trial, drug-related queries, and participant eligibility criteria, offering a comprehensive resource for families and caregivers. This e-booklet is a written counterpart to the webinar series, providing an alternative format for accessing essential information.
An expert team, including David Covini from DupMECP2, Katie Wester-Neal from the MECP2 Duplication Foundation, Dr. Davut Pehlivan from NRI Houston, and representatives from Ionis have answered each question in the e-booklet. Their insights ensure that every response is accurate.
We encourage you to watch the webinars, read the e-booklet, and share these resources with anyone who may benefit from them.


